Honghao Bio-Tech

Honghao Biotech, a subsidiary of CSPC Pharmaceutical Group, is a prominent Chinese biopharmaceutical company specializing in the development and manufacturing of recombinant protein drugs. Founded in 1998 and based in Beijing, the company is a pioneer in the production of cytokines within the Chinese market. Its flagship product, Anfulong (Recombinant Human Interferon alpha-2b), is a widely recognized treatment for chronic viral hepatitis and various oncological conditions. The company operates state-of-the-art GMP-certified facilities dedicated to biologics production, ensuring high-quality standards for its therapeutic portfolio. As part of the CSPC Group, Honghao Biotech leverages extensive R&D and commercialization networks to maintain its leadership in the interferon segment.